In a @ week , double-blind , randomized , controlled Phase @ study in patients with type @ diabetes mellitus , the addition of fixed-dose exenatide twice daily ( BID ) to titrated insulin glargine resulted in significant glycated hemoglobin ( HbA ( @c ) ) lowering and weight loss without increased hypoglycemia risk versus titrated insulin glargine alone .